Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Bayer halts vilaprisan drug trials due to toxicology data

Bayer halted trials testing the experimental uterine fibroids treatment vilaprisan, which the company previously expected to generate peak annual sales of more than 1 billion euros ($1.1 billion), citing the risk of side effects.

Read More »

Affimed puts on hold cancer drug trial after patient death

Affimed N.V. put on hold the testing of the drug developer’s experimental cancer drug following the death of a patient and two life-threatening events.

Read More »

Some Seattle Genetics drug trials placed on hold

Seattle Genetics said four people died in trials testing its experimental cancer drug, prompting the U.S. FDA to impose a clinical hold on several early-stage studies.

Read More »

Two more patients die in Juno leukemia drug trial

Juno Therapeutics Inc. said two more patients had died after suffering brain swelling during a trial of its experimental genetically engineered leukemia drug.

Read More »

Arrowhead Hep B Study Placed on Clinical Hold

Shares of Arrowhead Pharmaceuticals were down after the company’s experimental hepatitis B drug, ARC-520, was placed on clinical hold by the U.S. FDA.

Read More »

AstraZeneca pauses two cancer drug trials’ enrollment due to bleeding

AstraZeneca’s high hopes for cancer immunotherapy were dented as the recruitment of new patients with head and neck cancer into two clinical studies was put on hold, following instances of bleeding.

Read More »

FDA Slaps Partial Hold on Bay Area Firm Aduro Biotech’s Cancer Vaccine Trial

The U.S. FDA placed a partial hold on Berkeley, Calif.-based Aduro Biotech’s LADD trials.

Read More »

Regeneron, Teva pain-drug study on clinical hold

Regeneron and partner Teva said the U.S. health regulator placed a clinical hold on a mid-stage study of their experimental drug for chronic lower back pain.

Read More »

FDA Lifts Clinical Hold On CGF166

GenVec was notified by its collaborator Novartis that FDA has lifted the clinical hold on the Phase 1/2 clinical trial of CGF166 in patients with severe to profound hearing loss.

Read More »

Zafgen halts obesity drug trial after second patient death

Zafgen Inc said the U.S. Food and Drug Administration was putting a late-stage study testing its experimental obesity drug on complete hold after a second patient died during the trial. The company’s shares fell 7.4 percent to $5.81 in extended trading after closing down 60 percent on Wednesday. A complete clinical hold is an order […]

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

April 2019 Focus: Healthcare agency & network profiles, industry overview & awards, and more!


Ad Right Bottom